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Toufic El Arnaout1,2,* and Tewfik Soulimane3,4
Decades have passedwithout approval of a new antibiotic class. Several compa-
nies have recently halted related discovery efforts because of multiple obstacles.
One promising route under research is to target the lipoprotein maturation path-
way in light of major recent findings and the virulence roles of lipoproteins. To
support the future design of selective drugs, considerations and priority-setting
are established for the main lipoprotein processing enzymes (Lgt, LspA, and
Lnt) based on microbiology, biochemistry, structural biology, chemical design,
and pharmacology. Although not all bacterial species will be similarly impacted
by drug candidates, several advantages make LspA a top target to pursue in
the development of novel antibiotics effective against bacteria that are resistant
to existing drugs.
Antibiotic Design by Targeting Lipoprotein Maturation and Multi-Objective
Planning
Bacteria versus Hydrophobic Antimicrobial Designs: An Unpredictable Contest
Despite the importance of antibiotic development, leading pharmaceutical companies have re-
cently halted related projects owing to several challenges (Box 1). However, new antibiotics, par-
ticularly from novel classes, will be necessary to tackle the emerging crisis of bacterial
antimicrobial/antibiotic resistance.
Potential druggable sites may be predicted using bioinformatics tools and protein structures. In
the case of the three main enzymes, the topic of this review (Figure S1 in the supplemental infor-
mation online), these sites are generally accessible from the membrane bilayer and are located at
the periplasmic side of the cytoplasmic membrane. It might be easier for drugs to reach these
sites than having to cross the cytoplasmic membrane entirely. Nonetheless, drugs must cross
layers, diffuse in the cytoplasmic membrane, bind, and have hydrophobic properties. The
chemical design needed for such drug characteristics is difficult to predict. Molecules can violate
the predicted balance of aqueous versus membrane solubilities, as well as many criteria
in the ‘Golden Triangle’ and the Lipinski’s ‘rule of five’ (Ro5) [1,2] which evaluate properties
related to stability, absorption, permeability, potency, distribution, metabolism, and clearance
(e.g., ADMET criteria, see Glossary). Lipophilicity in drugs can be challenging [3] and can limit
drug candidates during prediction and selection steps. Another difficulty may be in adding lipophilic
properties topeptidomimetic scaffolds [4], which complicates it further in terms of rigid conforma-
tions, robust synthesis protocols, stability, resistance against degradation, and membrane pene-
tration efficiency [5]. Nevertheless, molecules often prematurely considered unattractive for drug
development pipelines sometimes pass clinical development and have a distinctive membrane
permeability [6]. The differences between bacterial species also have impact on how effective a
drug will be, such as the envelope and membrane composition, the survival mechanisms, and
the lipoprotein processing enzymes and lipoprotein forms they possess (Figure 1). Overall, the
antibiotic discovery pipeline employs disciplines including microbiology, biochemistry, structural
biology, pharmacology, organic chemistry, chemical synthesis, and formulation.
Highlights
The characteristics of the lipoprotein pro-
cessing enzymes Lgt, LspA, and Lnt
imply lipophilic, membrane-penetrating
antibiotic designs, of which the pharma-
cological qualities for administration
must be evaluated cautiously.
Each enzyme varies in relevance across
bacterial species, some of which also
possessmultiple genes and/or functional
homologs. Other enzymes and lipopro-
tein forms may also exist.
Structural comparison of Lgt with other
families (PgpBandPlsY) indicates unique
insights into inhibition and the lipid-
binding cleft.
The mechanism of binding of the LspA
inhibitor globomycin requires further
studies. Several hypotheses are pro-
vided on its inhibition type and interac-
tions with the catalytic site and protein
in general.
A novel LspA inhibitor, 'inhibitor-99',
shares similarity with known binders of
various proteins.
Lnt has four catalytic residues, to which
substrate access is controlled by a
unique lid-loop.
There is an additional pocket in Lnt for
binding and stabilization that lies above
the catalytic residues: lessons learned
from other protein families (DHHC20
and PlsC).
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In this review, to support antibiotic development efforts, interpretations related to these disciplines
are therefore raised for the three main lipoprotein maturation enzymes, Lgt (diacylglyceryl trans-
ferase), LspA (signal peptidase), and Lnt (N-acyltransferase), motivated by recent discoveries
such as the elucidation of their crystal structures [7–12]. The substrates of these enzymes are
pre-prolipoproteins, prolipoproteins, and apolipoproteins, respectively [13]. Lipoproteins are
encoded by 1–3% of the bacterial genome, and this corresponds to 30–80 genes on average.
Lipoproteins have different modified forms (Figure 1) and are involved in diverse functions such
as cell division, adhesion, infection, and virulence. Furthermore, we have carried out analyses of
enzymes with similarities to the main lipoprotein maturation enzymes, but that are from different
families, as well as analyses of several binding molecules and inhibitors, to highlight enzymatic
and inhibition mechanisms from unique viewpoints. Finally, we discuss the targets of foremost
potential impact for drug targeting among Lgt, LspA, and Lnt.
Species Dissimilarities and Other Pathway Enzymes: Implications for Novel
Antibiotics
A summary of several possible lipoprotein modification pathways (Lgt, different LspAs and Lnts,
Lit, deacylase) is shown in Figure 1. Currently, among these enzymes, the standout candidates
for drug discovery are Lgt, LspA, and (classic) Lnt because they are well characterized both func-
tionally and structurally [7–12]. Lgt, LspA, and Lnt are not essential or present in all types of bac-
teria, mostly depending on the bacterial GC content classification, membrane properties
(i.e.,Gram-positive, G+; orGram-negative, G−) and envelope architecture, and the presence
of functional homologs [14–21]. Of note, no significant homologs have been identified in Archaea,
although the substrate lipobox sequence is conserved [22].
In G− bacteria, the trio is generally considered to be essential, although recent studies showed
that this is not always the case for Lnt, and diacylated lipoproteins (i.e., not modified by Lnt)
may also still be secreted to the outer membrane without being triacylated [14,15]. Furthermore,
Myxococcus xanthus, a G− bacterium that produces myxovirescin (an LspA inhibitor), has four
lspA genes [16].
In G+ species the essentiality of Lgt and LspA also varies [17]. In some mycobacteria Lgt may be
essential, but LspA is not [17]. Some G+ bacteria (e.g., Clostridium difficile) express two non-
identical LspAs (LspA and LspA2) [18,19]. LspA can also act independently of Lgt [18,23]. Strep-
tomyces spp. (some produce globomycin, an LspA inhibitor) encode two Lgt homologs and two
Lnt homologs [20]. Furthermore, in G+ bacteria, the usual (E. coli-type) Lnt is generally present in
Box 1. General Challenges in Bringing a New Antibiotic to the Market
It is increasingly difficult for new molecules in general to reach the market, and biopharmaceutical research and develop-
ment returns dropped from 10.1 to 1.9 % between 2010 and 2018 [86]. In the context of antibiotics, some of the
challenges are:
(i) Slow and costly research process to discover a potential antibiotic.
(ii) Very short (small) return on investments.
(iii) Extremely low antibiotic discovery and approval rates compared to other drug types.
(iv) A regulatory burden throughout the process of validating and approving a new antibiotic.
(v) An antibiotic is usually consumed for a short period, and new antibiotics can be expensive. Clinicians will only use
them as a last resort, may not prescribe them immediately, to try to prevent the emergence of resistance.
(vi) Drug delivery obstacles owing to the complex chemical properties of antibiotics, the physiological location of bac-
teria in the host organism, and/or bacterial protection (e.g., membrane, biofilms, pH modulation).
(vii) Genetic andmicrobiological differences between species; an antibioticmay be effective against some species but
not against others (examples are highlighted here in the context of lipoprotein biogenesis enzymes), and antibiotic
resistance mechanisms may be stronger in some species than in others [84,85].
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GC-rich species, whereas in low GC-content species a different and unusual Lnt may facilitate
triacylation (Lnti) [21]. Interestingly, low GC-content G+ species may harbor additional modifica-
tion enzymes (e.g., Lit, Lntii, deacylase) and lipoprotein forms that are also unusual [24,25], as de-
scribed in detail in Figure 1.
Trends in Biochemical Sciences
Figure 1. An Illustration of Different Lipoprotein Modification Pathways. (A) The classic Lgt/LspA/Lnt pathway [13] showing the membrane proteins Lgt (pre-
prolipoprotein diacylglyceryl transferase), LspA (prolipoprotein signal peptidase), and Lnt (apolipoprotein N-acyltransferase). The solved structures of the three enzymes
are shown (PDBs 5AZC, 5DIR, and 5N6L [7,8,11]), together with the lipoprotein modifications at each step. Briefly (and not shown), a typical pre-prolipoprotein sequence
has an N-terminal signal peptide (SP), followed by a conserved cysteine (the first residue, Cys+1, of themature protein). The pre-prolipoprotein has a ‘lipoboxmotif’with four
characteristic amino acids numbered −3, −2, −1 andCys+1. Residues −3 to −1 correspond to the last three C-terminal residues of the SP. Lipidmodification by Lgt occurs
at Cys+1 of the lipobox, then LspA cleaves between residues −1 and Cys+1 to remove the SP, and Lnt adds an acyl chain to Cys+1. Once processed by all three enzymes,
the final lipoprotein is triacylated and lacks the signal peptide. In studied Gram-positive (G+), lowGC-content bacteria [21,25], ‘Lnti’ seemingly has a different sequence and
structure from the E. coli-type Lnt. (B) Additional lipoprotein forms (peptidyl, acetyl, and lyso [25]) and their processing enzymes in someG+ bacteria of lowGC content. The
peptidyl form results from proteolytic processing by an unusual LspA (LspA′) two residues before the Cys+1. The acetyl form is probably generated by a different enzyme
(‘Lntii’) rather than by Lnti. The lyso form results from either Lit (intramolecular transacylase [24]) or a deacylase, using the diacyl or triacyl form, respectively. The topology
shown for Lit is our predicted model (although a study predicted four rather than three transmembrane helices [24]).
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Figure 2. The Gating Transmembrane Helices (TMHs) and Lipid Inhibition in Lgt, PgpB, and PlsY. (A) The structures viewed from the front (top row) and from
the periplasm (Lgt and PgpB) or cytoplasm (PlsY) (bottom row) (PDBs 5AZB, 5JWY, and 5XJ8 [7,32,33]). Lgt, PgpB, and PlsY are bound to the inhibitors palmitic acid
(Figure legend continued at the bottom of the next page.)
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Other than the microbiology and genomics described above, we further elaborate on Lgt, LspA,
and Lnt in the following three sections to guide additional understanding of each enzyme and the
design of selective antibiotics.
Lgt: Binding and Inhibition Insights Based on Phospholipid Biosynthesis
Enzymes
Two Binding Clefts and an Induced-Fit Mechanism Characterize Lgt
Lgt has seven transmembrane helices (TMHs). TMHs 1–2 constitute the ‘front cleft’ through
which binding of the lipid-donor phosphatidylglycerol (PG) occurs in site 1. PG may also slide
into an interior site 2, the catalytic site (Figure 2A). Furthermore, TMHs 3 and 7 constitute the
‘side cleft’ for binding the acceptor domain of the protein [7]. Lgt has a conserved HGGL motif
that is important for transacylation (this motif contains His103 in the side cleft) (Figure 2).
In the two solved structures, site 2 was occupied by diacylglycerol (DAG) or palmitic acid (inhib-
itor); DAG likely originated from PG hydrolysis [7]. In site 1, PG directly interacts with Met100,
Trp256, and Val257, or with His24, while in site 2 both DAG or palmitic acid interact with
Arg143/Tyr30 [7] (Figure 2A,B and Figure S2). Arg143 and Arg239 are close to each other and
are vital for diacylglyceryl transfer (Figure 2A).
Inhibition of the entry and binding of the lipid donor PG at site 1, or at site 2, is therefore important
to restrict the enzymatic activity of Lgt towards the acceptor pre-prolipoprotein. Note that two po-
tential mechanisms [7] follow PG entry into site 1 (initially independent of pre-prolipoprotein bind-
ing): (i) PG slides into site 2 (the catalytic site) and the reaction occurs upon binding of the acceptor
at site 2, or (ii) PG only slides into site 2 owing to induced-fit and gate control in Lgt that is asso-
ciated with acceptor binding at site 2. PG slidingmay be controlled by a gate close to Arg143. It is
important to determine whether the main target should be (i) site 1, (ii) site 2 (from site 1, probably
based on an induced-fit structure), or (iii) perhaps the side cleft. The inhibited protein form with
palmitic acid may provide insights into specific interactions for drug candidates (Figure 2B), al-
though palmitic acid is not a strong or specific inhibitor. Further, palmitic acid cannot be used clin-
ically because it binds to many proteins [26] and interacts (as in Lgt) with an arginine in kinases,
nuclear factors, albumins, cytochromes [27], and α-dioxygenases [28]. Therefore, structure–
function studies of Lgt with more specific inhibitors will be necessary for future drug design. Spec-
ificity must be developed by exploring the unique features of Lgt versus similar proteins from other
families – such as unique interaction residues and lipid-binding pocket properties – or by targeting
the side cleft instead of the lipid-binding cleft.
Structural Comparison with Phospholipid Biosynthesis Enzymes for Specific Lgt Inhibitor Design
Lgt binds a PG as a donor. Enzymes from other families, particularly those involved in phospholipid
synthesis pathways [29], also bind or produce similar lipids during their reactions, andmany aremem-
brane proteins with TMHs and a lipid-binding gate as in Lgt [7]. It is remarkable how each may selec-
tively react with, produce, or undergo inhibition by lipids of strong resemblances. Hence, we compare
Lgt with two othermembrane enzymes,PgpB (phosphatidylglycerol-phosphate phosphataseB) and
Glossary
ADMET: absorption, distribution,
metabolism, excretion, and toxicity.
These properties of a potential drug are
studied during development to
understand the effects on an organism
and the suitability and safety for
administration.
Amidase: an enzyme from the large
family of hydrolases; amidases catalyze
the hydrolysis of an amide bond.
Diacylglycerol (DAG): an intermediate
formed during some enzymatic
reactions involving lipids; also a







Enterobacter species) that are often
cited in the context of antibiotic
resistance.
G3P acyltransferase (GPAT):
examples of GPAT enzymes in this
review include PlsB and PlsY.
GC content: guanine and cytosine
content (percentage) in genomic DNA.
Glycerol-3-phosphate (G3P): used
together with an acyl donor by the
proteins PlsY or PlsB to produce the
phospholipid, lysophosphatidic acid
(lysoPA).
Gram-negative (G−): bacteria such as
Escherichia coli and Pseudomonas
aeruginosa. They usually have a very thin
layer of peptidoglycan and an outer
membrane.
Gram-positive (G+): these bacteria
usually have a thick cell wall with layers of
peptidoglycan and no outer membrane.
Lipobox: it contains a motif of four
residues in the lipoprotein precursor,
which are the last three (C-terminal)
residues of the N-terminal signal peptide
(10–20 residues), and the conserved
cysteine that follows (this cysteine
becomes the first residue in the mature
protein). Lgt adds a diacylglyceryl moiety
onto the cysteine, LspA cleaves the
(marked with a blue triangle, in site 2, close to Arg, behind phosphatidylglycerol, PG), phosphatidylethanolamine (PE), and lysophosphatidic acid (lysoPA), respectively. The
TMHs in magenta (numbered) are likely the gates for lipid binding. In PgpB the upper diverging part related to TMH2 (named the α1-helix [30]) is in lighter magenta. Selected
important residues are labeled as red sticks. The TMHs in orange in Lgt are the binding side (side cleft) of the protein substrate. (B–D) Selected regions of Lgt, PgpB, and
PlsY. Lipids are shown as sticks. Residues according to the direct interaction maps (Figures S2 and S3) are colored in red and labeled with grey circles. (B) Inhibited (PDB
5AZB, lipids in yellow) versus normal Lgt (5AZC, lipids in black) forms (front view as in A, top), with lipids at site 1 (at TMHs (H) 1 and 2) and site 2 (further behind). Site 2 is
where DAG (PGT2) or palmitic acids (PLM2 and the inhibitor PLM1) are bound. Selected interactions are with residues Y, R, and H (5AZB), or Y, R, M, W, and V (5AZC).
(C) Top views towards the gate regions of inhibited Lgt (left) versus inhibited PgpB (right) forms, with the bound lipids at the gates (substrate PG in Lgt or inhibitor PE in
PgpB). (D) Views towards the gate regions of inhibited Lgt (left) versus inhibited PlsY (right) forms, with the inhibitors palmitic acid and lysoPA, respectively. The figures
were generated using the PyMOL Molecular Graphics System (version 1.7.4.5 Edu, Schrödinger, LLC).
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PlsY [glycerol-3-phosphate (G3P) acyltransferase], whose structures in complex with lipid inhibi-
tors were recently solved (Figure 2).
PgpB (PDB 4PX7 [30]) appeared as a hit when using an online bioinformatics tool to search for
proteins with similar patterns and PDB structures to Lgt [31]. PgpB has prokaryotic and eukary-
otic homologs, and its structure with an inhibitor (Figure S3), phosphatidylethanolamine (PE) was
also determined (PDB 5JWY [32]). The two enzymes have some structural similarities (Figure 2A,
C), but threemain residues in PgpB aremore tightly positioned compared to those selected in Lgt
(Figure 2A) because Lgt has a more stretched structure. This may be explained by the features of
both proteins: PgpB has a front cleft, whereas Lgt has both front and side clefts, as well as visible
sites 1 and 2. The side cleft of Lgt (highlighted as TMHs in orange in Figure 2A) has the TMHs po-
sitioned more suitably for binding to the pre-prolipoprotein lipobox than TMHs located at a similar
angle in PgpB and PlsY (note, unlike Lgt and PgpB, the orientation of PlsY is towards the cyto-
plasm). Therefore, this cleft may provide a more specific target for designing inhibitors than the
front cleft for binding lipid donors.
PlsY is also a membrane protein and a transferase like Lgt. Unlike PgpB, PlsY has no eukaryotic
homolog. It catalyzes a reaction (acyl-phosphate + G3P) to form lysophosphatidic acid (lysoPA),
thus involving molecules smaller than those processed by Lgt. Interestingly, the structure of PlsY
was recently solved in the presence of an inhibitor (the product lysoPA, Figure S3) [33]. PlsY is
smaller than both Lgt and PgpB, and has a compact arrangement (Figure 2A). In Lgt, the side
cleft TMHs are very close to each other at the top, and then become distant towards the bottom,
unlike the corresponding TMHs in PgpB and PlsY. Furthermore, lysoPA is inside the structure of
PlsY, but palmitic acid in Lgt is deeper (Figure 2A,D). Both lysoPA and palmitic acid interact with
an arginine residue that is crucial for the activities of Lgt and PlsY. Interestingly, His177 in PlsY,
that is mainly indispensable for substrate positioning [33], seems at a similar position to His103
in Lgt relative to the lipid-binding gate and the bound lipids inside the structure (site 2 in Lgt).
LspA: Drug Design Recommendations Based on Four Distinct Molecules
Globomycin: Detailed Hypotheses to Clarify Its Controversial Mechanism
Globomycin [34,35] is an antibiotic lipopeptide (cyclodepsipeptide) which diffuses in the mem-
brane to the protein-binding site of LspA. The sensitivity of G− bacteria to globomycin may be in-
versely related to their lipopolysaccharide chain lengths [36]. Modifying the amino acid
composition of globomycin can play a role in the antibacterial efficacies of analogs, but in partic-
ular a long alkyl side chain (Figure 3) is important and its exact length may make globomycin even
more effective against G− bacteria, and to also become effective against G+ bacteria [37]. Such
studies are relevant to consider when optimizing species-specific analogs or synthesizing novel
peptides based on the essential features of globomycin.
Globomycin was cocrystallized with LspA [8] (Figure 3A). Its Leu–Ile–Ser sequence mimics the
first three lipobox residues [8] of the prolipoprotein [which can be (LVI)−3 (ASTVI)−2 (GAS)−1], in
other words the last three C-terminal residues of the signal peptide. The structure of globomycin
does not include a mimic of the fourth lipobox residue (Cys+1) and its linked DAG (Figure 1), nor of
residues +2 and+3 in the prolipoprotein substrate that would mimic the binding conformation of
substrate above the LspA aspartates (D123 and D143) at the membrane leaflet (Figure 3A).
Globomycin may be more of a mimic of the cleaved signal peptide product (it is common for
many proteases to be inhibited by product peptides).
In addition, despite binding at active aspartate residues of LspA, globomycin is not a ‘competitive’
inhibitor as claimed [8] but is ‘partially’ noncompetitive. In fact, the classification may depend on
several molecular and experimental conditions [38], and recently globomycin was suggested to
signal peptide at the N-terminus of the
cysteine, and Lnt transfers an acyl chain
onto the cysteine.
Low-barrier hydrogen bond (LBHB):
a short (less than ~2.5 Å) and strong
bond with midway hydrogen (certain
spectroscopic methods are necessary
to confirm this).
Nitrilases: a large superfamily of
enzymes, with multiple branches, that
hydrolyze non-peptide carbon–nitrogen
(CN) bonds; sometimes referred to as
CN hydrolases.
Peptidomimetic: a molecule designed
to mimic certain properties of a peptide.
This has advantages in drug research,
for instance in target inhibition.
Peptidomimetics are often based on a
known peptide but with some
modifications.
PgpB: phosphatidylglycerol-phosphate











Steric compression: it is a
characteristic of a certain steric effect
(sometimes using terms such as
crowding or hindrance) and
configuration in the binding mode of a
molecule (here, an inhibitor). The binding
mechanism can initially be slow. Further
experiments (e.g., using nuclear mag-
netic resonance, NMR) are necessary to
measure chemical shifts and validate the
hypothesis if this applies to globomycin.
X-bonding: halogen bonding involving
a halogen atom. The classic type
otherwise is hydrogen bonding.
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be noncompetitive [39], as was previously indicated by an experimental study (inhibitory constant
Ki=36 nM) [40]. We suggest that, when globomycin is tested against the entire enzyme (and in the
presence of substrates), the type of inhibitionmay be identified as ‘partially competitive’, or noncom-
petitive vis-à-vis the entire LspA. LspA bound to globomycin may thus still interact with part(s) of the
Trends in Biochemical Sciences
Figure 3. The Three Main Inhibitors of LspA and Binding Insights. (A) The structure of LspA (i.e., prolipoprotein signal peptidase, type II signal peptidase, Lsp,
SPase II, SPII). The transmembrane helices (TMHs) are numbered. Selected residues (yellow sticks) form direct hydrogen bonds with the cyclic antibiotic globomycin
(Figure S4). (A) and (B) were generated using the PyMOL Molecular Graphics System (version 1.7.4.5 Edu, Schrödinger, LLC) and PDB 5DIR [8]. (B) A closer look at
bound globomycin. The selected residues in (A) are shown in yellow in the protein (‘surface’ presentation). Globomycin is in ball-and-stick mode, with the main atoms
in magenta, and those generally involved in direct interactions in orange. The main hydroxyl is further labeled as ‘dotted sphere’ at the catalytic aspartates.
(C) Chemical structure of globomycin and analogs SF-1902 A2–A5. Figure adapted, with permission, from [45]. The atoms involved in hydrogen bonding with LspA
(based on all chains in PDB 5DIR) are highlighted in blue circles; an orange dashed circle indicates the hydroxyl interacting with the aspartates. (D) Inhibitor-99 (figure
adapted, with permission, from [39]) and its isomers identified for this review using Chemicalize (https://chemicalize.com/; developed by ChemAxon, http://www.
chemaxon.com). Common features are highlighted in orange. The isomers (named compounds A–F) were described in patents as activators or inhibitors of various pro-
teins (Table S1). (E) The chemical structures of myxovirescin and analogs [50,51] (figure adapted, with permission, from [79]). Myxovirescin B is nearly identical. The labels
are hypothetical and are based on the analysis in this figure (B and C) and in Figure 4.
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prolipoprotein substrate (e.g., the DAG of the cysteine and/or the top part at the exoplasmic leaflet).
Globomycin may also bind through a two-step mechanism [38]. The interactions of unbound LspA
with the prolipoprotein substrate may involve different parts of the substrate, resulting in more than
one product (e.g., cleaved signal peptide and apolipoprotein), and cause multiple conformational
changes in LspA (before, during, and after cleavage). Inhibition by globomycin may only correspond
to one LspA conformation and involve binding to only a small region of LspA, unlike the interaction of
LspA with the entire prolipoprotein substrate (which in particular has membrane and periplasmic
parts). This hypothesis highlights the importance of ensuring that, during drug development, inter-
pretation and optimization require a correct understanding both of the enzymology and of the most
favorable LspA conformation for designing stronger inhibitors.
Third, the positioning of globomycin within LspA probably occurs through a slow binding process
known as steric compression, resulting in a tight hydrogen bondwith the aspartates (Figure S4)
(e.g., low-barrier hydrogen bonds, LBHBs [41,42]). Its key hydroxyl sterically blocks the cata-
lytic aspartates Asp124 and Asp143 [8] (Figure 3B). A distorted aspartate coplanarity is likely
(e.g., [43]) when globomycin is bound (possibly to an initially dehydrated enzyme) compared to
when substrate is bound. There is no place for a water molecule (Figure 3B). Therefore, because
the necessary arrangement and geometries may not be present, there is nomimicking of the ideal
‘tetrahedral’ configuration. This is the case of several other proteins in complex with inhibitors
wherein the hydroxyl displaces the water molecule, probably due to slow binding and/or confor-
mational changes during binding. Thus, it is important to verify if globomycin truly mimics the tran-
sition state, and to study the LspA conformations.
Fourth, additional stereochemical features are also important in globomycin. Analysis of all chains
in the PDB was carried out to identify the main atoms involved in direct hydrogen bonding inter-
actions (Figure 3B,C), including the L-Thr hydroxyl (Figure 3C). Indeed, its stereochemistry was
determined to be important for activity [44,45]. Some structural similarities with pepstatin (a clas-
sic aspartate inhibitor discussed below) are also suggested in Figure S4.
Finally, there are microbiological ambiguities to explore. In Archaea, despite the absence of clear
LspA homologs, globomycin specifically inhibits lipoprotein maturation [46]. In mycobacteria, its
actionmay be independent of LspA [47], probably because it inhibits a similar or different enzyme.
In some G+ bacteria [18] there are two LspAs (LspA and LspA2), and only LspA is inhibited by
globomycin [19].
Inhibitor-99: Recently Discovered but Similar to Known Binders of a Variety of Proteins
‘Inhibitor-99’, so named here based on its IC50 of 99 nM, was discovered in a high-throughput
library screen against LspA [39,48]. It was identified (i.e., the tested analogs) as noncompetitive.
It is effective in conjunction with the outer-membrane permeabilizer polymyxin B nonapeptide
(PMBN). The structure is different from that of either globomycin or myxovirescin (Figure 3D).
Our search in chemical databases, including Chemicalize (https://chemicalize.com/; developed
by ChemAxon, http://www.chemaxon.com), revealed isomers that were reported to be inhibitors
of diverse proteins (Figure 3D and Table S1). Therefore, the specificity (prokaryotic vs eukaryotic
proteins) and selectivity should be clinically verified.
Myxovirescin: Different from and More Potent Than Globomycin
Also known as antibiotic TA, megovalicin, andM-230B (Figure 3E), the properties of myxovirescin
suggest membrane penetration similarly to globomycin. It belongs to a largemacrolactam lactone
family and has no toxicity towards eukaryotic cells [49]. Known for half a century, it recently
resurfaced as a specific LspA inhibitor that is more potent than globomycin [50,51]. A rarely men-
tioned derivative known as ‘focusin’ (hydrogenated form) is more stable but has a lower specific
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activity [52]. A novel assay [39] determined an IC50 of ~1.2 nM for both myxovirescin and
globomycin, indicating potency against LspA.
Pepstatin: Research on Its Derivatives Is Valuable for Enhancing Existing LspA Inhibitors
Because LspA is an aspartate protease, the peptide pepstatin – a classic inhibitor of several aspartate
proteases – is reviewed here. There are few studies on its effects on LspA [53], but one paper re-
ported an IC50 of 0.32 mM [54]. Generally, pepstatin interacts with targets through a hydrogen
bond network (Figure 4). The γ-amino acid statine within pepstatin makes pepstatin nonhydrolyzable
and a tetrahedral transition state mimic, and is also incorporated into many HIV protease and renin
inhibitors [55]. Nevertheless, as with globomycin, the main hydroxyl at the aspartates may in some
cases be tightly bound without space for water (see above). Designs with statine-based cores are
common (Figure 4), for example ‘inhibitor a’ [5] against plasmepsins [56] and a phosphonated
Trends in Biochemical Sciences
Figure 4. A Chemical Overview of Aspartyl Protease Inhibition Design and Principles. (A,B) Basic components and derivatives that are often incorporated into
inhibitors based on statine and hydroxyethylamine (figures adapted, with permissions, from [5,56]). (C) Pepstatin A containing statine (Sta) in the middle with the key hydroxyl
is highlighted, as well as other atoms involved in hydrogen bonding, based on the structure of pepsin–pepstatin [87]. Inhibitor a, that was reported to be a very active inhibitor
of the aspartate proteases plasmepsin (Plm) I and II is shown (figure adapted, with permission, from [56]), based on a statine-reversed core. (D) (Left) The 3D structure of a
phosphonate form, similar to pepstatin A, using NGL Viewer [88] (RCSB.org database), based on the human pepsin A PDB 1QRP [57]. (Right) A proposed design standard
that is selective (Plm I and II inhibitors), containing a statine core (figure adapted, with permission, from [5]). Abbreviation: LeuP, phosphinic acid analog of L-leucine.
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form that forms a short hydrogen bond [57]. The hydroxyl may be also replaced by other atoms.
We believe that there is structural similarity with globomycin (Figure S4). If derivatives against
LspA are developed, their cell penetration ability [58] should be ensured. Perhaps lessons can
be drawn from developments for other intramembrane proteases (e.g., rhomboids [59]).
Lnt: A Nitrilase with Many Unique Features
A Catalytic Tetrad C–E–E–K in the Nitrilase Domain Is Close to the Transmembrane (TM) Domain
Lnt is an unusual nitrilase (reverse amidase [60]) that is connected to a TM domain [9–12]
(Figure 5). The nitrilase superfamily has a conserved Glu–Lys–Cys catalytic triad (prokaryotes and
eukaryotes) [60]. However, some nitrilases have a tetrad (C–E–E–K) owing to a fourth conserved
catalytic residue (Glu) (e.g., formamidases [61]). In Lnt (triad E267–K335–C387), the conserved
E343 near the triad is almost fixed in all structures [62], despite its proximity to highly flexible regions
(Figure 5A). E343may facilitate recognition of the donor lipid as well as the formation of the Lnt–lipid
intermediate and stabilization of K335 in the triad [10], thus it is important for catalysis overall, par-
ticularly for the lipid-binding reaction (first step). Likewise, in some amidases, a similar Glu residue
was proposed to be involved in substrate positioning [63]. Thus, as in nitrilases previously [61],
we suggest also naming the Lnt catalytic element a ‘tetrad’. Other unique features in Lnt are a lid-
loop (that may protect the binding cavity) and a phosphate-binding site.
A Long Flexible Loop May Act as a Lid to Restrict Access of Molecules from the Periplasm
A unique loop (compared to soluble nitrilases) contains a short helix and a flexible amphipathic lid-
loop (F357–Q372) [10] that may enforce its membrane anchoring. As determined from six Lnt struc-
tures, the sequence of highest divergence and flexibility is F344–S363 (Figure 5A) [62]. Therefore,
here, based on the comparisons of this entire sequence, we describe the lid-loop and its conforma-
tions differently, and may call it ‘loop 3xx’. Its electron density is partly missing in most structures.
Clearly, it is adjacent to E343 and may identify a potential druggable site (Figure S1).
The loop likely restricts periplasmic access to the binding groove of Lnt by freemolecules not orig-
inating from the membrane (Figure 5A, left) by controlling the interface as a lid that maintains con-
tact with the membrane. Therefore, only lipid donors from the membrane are able to bind.
Hypothetically, when the loop is raised (high position), it acts as a closed lid, and when lowered
and to the side, following the lipid-donor binding, it adopts the ‘open’ position (Figure 5A, middle).
Therefore, it is also expected that the open/lowered position permits the anchorage of the apoli-
poprotein (Figure 1) at the cavity of Lnt. As a side note, residue F82 (opposite to the loop) that was
previously proposed to be a gatekeeper [9] (for the lipid donor at the binding site, assuming that
the loop is in the low position at all times) appears not to play such a role in the present lid-loop
(low vs high) hypothesis, and this would also explain why a F82 mutant [9] had no effect.
During the first step of the reaction, part of the lipid donor forms the Lnt–acyl intermediate, while
the other part is released. The acceptor apolipoprotein then becomes anchored for the second
step of the reaction. Note that some structures were solved with the loop in the ‘open’ position,
and do not contain relevant bound lipids [11]. Which loop conformation was obtained in a struc-
ture probably depends on the crystallization method used and crystal packing. A very recent
study also suggested this possibility [12], to be due for example to the added detergents, the
presence of artificial lipids during crystallization, and/or crystalline molecular packing. This study
identified a Lnt intermediate form (thioester acyl intermediate, chain B; PDBs not available), with
an even more upward (higher) loop compared to that labeled in the red ribbon in Figure 5A. It is
unlikely that this new conformation permits the loop stabilization with the membrane, or the bind-
ing of the apolipoprotein, also because in several PDBs with bound lipids the loop was in the
open/low position (yellow ribbon in Figure 5A). Therefore, the positions proposed in Figure 5A
may be more likely. Analysis of the loop is important to consider when designing inhibitors, in
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Figure 5. Conformation Models of the Lid-Loop and the Phosphate-Binding Site of Lnt. (A) Flexibilities of the loop and the phosphate-binding residues. (Left) Lnt
structure (PDB 5XHQ [10] was used as a template). The two conformations of the proposed lid-loop (‘loop 3xx’), closed/raised and open/lowered, are as observed in PDB
5XHQ (red ribbon, invisible density manually completed here) and PDB 5N6H [11] (yellow ribbon), respectively. When raised, it restricts against periplasmic molecules but
allows lipid donor access from the membrane leaflet. Then, in the open position in the Lnt–lipid intermediate, the apolipoprotein may bind. (Middle) A closer view, with the
catalytic tetrad shown as green sticks (E267–K335–E343–C387). The green dotted sphere represents the chloride superimposed from PDB 5VRH [9]. (Right) Potential
phosphate-binding residues. Residues W237, K236, Q233, and W415 are highlighted as red (PDB 5N6H [11]) or yellow sticks (PDB 5VRH [9]) (loop in open position in both
PDB structures). The difference may correspond to stabilization by, and interaction, with an element such as chloride (green sphere) or the head group of the lipid donor.
(B) Three acyltransferases, Lnt, PlsC, and a DHHC enzyme, that rely on the membrane. The purple horizontal line is an approximation of the level of the membrane, and the
protein features in magenta represent the transmembrane helices in Lnt (PDB 5VRG) and DHHC20 (Golgi body membrane, PDB 6BMN) or the two-helix anchoring motif in
PlsC (to the inner leaflet of the inner membrane) (PDB 5KYM) [9,69,70]. The yellow cross indicates the potential binding locations of the phosphate groups of ligands. Bound
acyl chains in Lnt and DHHC20 can be seen, while in PlsC (acyl donor not shown) the drawn oval indicates the potential position of lysophosphatidic acid [70]. Selected
residues are highlighted as red sticks. The figures were generated using the PyMOL Molecular Graphics System (version 1.7.4.5 Edu, Schrödinger, LLC).
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assessing whether they will bind, and in determining whether other designs should be explored to
block the Lnt–lipid intermediate in the open loop mode.
A Pocket for Stabilizing the Lipid Head Group Shows Flexibility
The phosphate recognition site in Lnt was hypothesized [9] based on a chloride ion interacting
with several residues (Q233, W237, K236, N412, W415) above the catalytic tetrad. These inter-
action residues include important and characterized residues [9,64] (Figure 5A). Interestingly, sol-
uble nitrilases may not contain such a pocket owing to further sequence extensions (Figure S5).
Comparison of all Lnt structures revealed flexibilities mainly of four of the phosphate interaction
residues, as shown in Figure 5A, but N412 was not highlighted because it has a similar position
in all PDB structures. Furthermore, based on the lid-loop hypothesis, this site may also be
protected against periplasmic molecules, and may mediate the selectivity and stabilization of
the lipid donor (e.g., PE, PG, or phosphatidic acid [65]) by binding its head group (e.g., POPE)
[9]). In the next reaction step, namely the binding and interaction with the protein acceptor, it is
also possible that the phosphate recognition site facilitates the docking of the apolipoprotein,
and perhaps interacts with residues +2/+3/+4 that follow the N-terminal conserved Cys+1
(Figure 1). The +2/+3/+4 residues have been shown to be important for the interaction of the li-
poprotein with complexes in other pathways [66–68] (see Outstanding Questions). Unfortunately,
it is unclear why the phosphate interaction residues are in the same position in both PDBs 5XHQ
(loop as ‘closed lid’) and 5VRH (open loop) (Figure 5A), despite a H2O built in the place of the chlo-
ride, and it is also unclear to what extent the position of the loop has an effect on these residues.
The recently solved structures of membrane-dependent acyltransferases from other families,
PlsC [1-acyl-sn-glycerol-3-phosphate (LPA) acyltransferase (LPAAT)] and DHHC20
[palmitoyltransferase (S-acyltransferase)] [69,70], also suggest the presence of a phosphate-
binding site (Figure 5B). The bacterial PlsC is anchored to the inner membrane (facing the cyto-
plasm) and uses lysoPA as a substrate that is usually generated by PlsB (G3P acyltransferase,
GPAT), to form phosphatidic acid (PA). PlsC contains a catalytic His84, a transition-state stabilizer
Lys105, and Arg159whichmay (mainly) bind the 3′-phosphate of lysoPA [70] (Figure 5B). The eu-
karyotic palmitoyltransferase DHHC20 [71] (human S-acyltransferase) is a Golgi TM protein with a
cytoplasmic domain that uses acyl-CoA donors (as do PlsB and PlsC) such as palmitoyl-CoA,
and has a catalytic DHHC motif. In Figure 5B, the physiological orientation of DHHC20
(Golgi body membrane) is towards the cytoplasm, as is PlsC (cytoplasmic membrane), whereas
Lnt (cytoplasmic membrane) is towards the periplasm. Furthermore, several DHHC20 residues,
of which two are labeled at the top (Figure 5B), interact with phosphate groups [69].
Inhibitor Design Against Lnt: What Can Soluble Nitrilases Tell Us?
As previously mentioned, Lnt has both a nitrilase and TM domains (Figures 1 and 5). For soluble
nitrilases, an acyl-transfer intermediate (acetohydroxamic acid derivative) was identified in an am-
idase structure [72], which is interesting because it is covalently bound. Furthermore, antiparasitic
lipophilic compounds, derivatives of acetohydroxamic acid, were tested [73,74]. Such studies
may guide the design of inhibitors of Lnt acyltransferase, and this will likely require hydrophobic
inhibitors that access from the membrane on which Lnt depends, according to its lid-loop restric-
tion against free periplasmicmolecules. In Lnt, lipid acyl chains also extend almost vertically below
the catalytic residues (Figure 5), as do ligands in soluble nitrilases (Figure S6). In addition, relevant
inhibitor enhancement functionalities may for example be halogens (forX-bonding), as previously
reported for a nitrilase [75]. Halogen bonds can be specific, directional, and noncovalent, with a
positive impact on binding and selectivity [76]. Furthermore, allosteric nitrilase or membrane do-
main sites may be also possible (Figure S1), but are probably less specific. Perhaps the acyl-Lnt
intermediate with an open loop as in Figure 5A, or the non-bound phosphate site (for a small
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inhibitor probably accessing near the lid-loop), may be also possible to target with other inhibitor
candidates; however, in this case it will be difficult to learn much from soluble nitrilases.
Concluding Remarks and Future Perspectives
Bacterial species possess several different modification enzymes and lipoprotein forms. In partic-
ular, Lgt, LspA, and Lnt were investigated in view of their central roles in lipoprotein biogenesis,
and to establish priorities for drug design pipelines. Lgt likely involves a two-step process with
an induced-fit conformation. It binds common lipids, and has structural similarities with other pro-
teins such as PgpB and PlsY, which raises the challenge of developing specific inhibitors. How-
ever, the other cleft for binding to the pre-prolipoprotein lipobox motif might be more suitable for
targeting, particularly if there is no need to inhibit the lipid-binding cleft simultaneously and if the
inhibitor binds to the correct Lgt conformation that mostly prohibits binding of the pre-
prolipoprotein. Note that in some species an additional Lgt may be present [20], and LspA may
act independently of Lgt [18,23]. As for LspA, it has the simplest structure, and has no homologs
in eukaryotes. Four molecules have been discussed in the context of inhibitor design against
LspA, and provide interesting clues compared to current data on Lgt and Lnt. Lnt seems, com-
pared to Lgt or LspA, less essential in many species or even not present [14,15,20,21,24,25].
Furthermore, several enzymes (e.g., Lit or unusual Lnts) other than the E. coli-type Lnt may
carry out modifications [20,21,24,25]. Pursuit of Lnt inhibitors will require that the specific dynam-
ics of the structure (e.g., the loop and phosphate-binding site) are further characterized, and may
provide advantages compared to soluble nitrilases [60].
Overall, LspA is recommended for future drug discovery pipelines over Lgt and Lnt. Note, how-
ever, that there will be limitations to the range of pathogens that can be targeted based on their
cellular barriers and the presence of a non-essential LspA or multiple LspAs [16–19,37]. Potential
antibiotics should be also tested in different species to determine whether they might act similarly
to globomycin that can be LspA-independent [46,47]. One potential advantage of targeting LspA
is that the solved variant structure of LspA [8] was based on the Pseudomonas aeruginosa pro-
tein (one of the ESKAPE pathogens). Furthermore, the knowledge of several inhibitors pre-
sented here may be combined with that of known engineered pepstatins, and implemented
into novel designs, while taking into consideration the described hypotheses on the mechanism
of LspA inhibition based on globomycin.
In terms of hypothetical drug design, organic chemistry seems to be crucial to enhance the sta-
bility and efficacy of lipophilic peptidomimetics [77,78], as well as their permeability across the li-
popolysaccharide layer of G− bacteria [36,79], while minimizing clinical challenges (ADMET). An
accelerated route might be to explore microorganisms for natural products [80], as in the case
of globomycin [34,35] and myxovirescins [51] or other macrolides (with a lactone ring [81]),
and to study bound structures and conformations using powerful structural biology techniques
[82,83] (see Outstanding Questions).
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